© 2001 by European Society of Cardiology
SYNCOPE
Components of clinical trials for vasovagal syncope
Cardiovascular Research Group University of Calgary Calgary, Alberta, Canada
Abstract
The time is ripe for adequately powered, randomized, placebo-controlled clinical trials in vasovagal syncope. Vasovagal syncope is a common syndrome, the symptoms of which can be troublesomely frequent. It is usually diagnosed by tilt-table testing, although this has persistent problems with both sensitivity and specificity. Patients with syncope and positive tilt tests have been the subjects of numerous studies of natural history, risk stratification, and treatment. This paper discusses studies of treatments for vasovagal syncope in the context of a classification of the levels of evidence that can be gleaned from clinical studies. The reasons for placebo-controlled trials are reviewed, as is the evidence for various methods of risk stratification. Data for power calculations are presented for the primary outcome, the time to the first syncope recurrence. Strengths and weakness of the four main types of outcomes for clinical trials are compared.
Key Words: Vasovagal syncope, tilt-table test, randomized clinical trials, quality of life, cost utility, drug therapy, pacemaker therapy
Correspondence: Dr Robert Sheldon, Faculty of Medicine, University of Calgary, Health Sciences Centre, 3330 Hospital Drive NW, Calgary, Alberta T2N 4N1, Canada. E-mail: sheldon{at}ucalgary.ca
References
[1] Cook DJ, Guyatt GH, Laupacis A, Sackett DL. Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 1992; 102: 305S–311S.
[2] Benditt DG, Ferguson DW, Grubb BP, et al. Tilt table testing for assessing syncope (review). J Am Coll Cardiol 1996; 28: 263–275.[CrossRef][Web of Science][Medline]
[3] Di Girolamo E, Di Iorio C, Sabatini P, Leonzio L, Barbone C, Barsotti A. Effects of paroxetine hydrochloride, a selective serotonin reuptake inhibitor, on refractory vasovagal syncope: A randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 1999; 33: 1227–1230.
[4] Lee TM, Su SF, Chen MF, Liau CS, Lee YT. Usefulness of transdermal scopolamine for vasovagal syncope. Am J Cardiol 1996; 78: 480–482.[CrossRef][Web of Science][Medline]
[5] Zeng C, Zhu Z, Liu G, et al. Randomized, double-blind, placebo-controlled trial of oral enalapril in patients with neurally mediated syncope. Am Heart J 1998; 136: 852–858.[CrossRef][Web of Science][Medline]
[6] Di Girolamo E, Di Iorio C, Leonzio L, Sabatini P, Barsotti A. Usefulness of a tilt training program for the prevention of refractory neurocardiogenic syncope in adolescents: A controlled study. Circulation 1999; 100: 1798–1801.
[7] Ector H, Reybrouck T, Heidbuchel H, Gewillig M, Van de Werf F. Tilt training: A new treatment for recurrent neurocardiogenic syncope and severe orthostatic intolerance. Pacing Clin Electrophysiol 1999; 21: 193–196.
[8] Raviele A, Brignole M, Sutton R, et al. For the Vasovagal Syncope International Study Investigators. Effect of etilefrine in preventing syncopal recurrent in patients with vasovagal syncope. A double blind, randomized, placebo-controlled trial. Circulation 1999; 99: 1452–1457.[Medline]
[9] Ward CR, Gray JC, Gilroy JJ, Kenny RA. Midodrine: a role in the management of neurocardiogenic syncope. Heart 1998; 79: 45–49.
[10] Natale A, Beheiry S, Tomassoni GF, et al. Randomized placebo controlled assessment of midodrine in the treatment of neurocardiogenic syncope (Abstract). J Am Coll Cardiol 1999; 33: 269A.
[11] Mahanonda N, Bhuripanyo K, Kangkagate C, et al. Randomized double-blind, placebo-controlled trial of oral atenolol in pateints with unexplained syncope and positive upright tilt table tests results. Am Heart J 1995; 130: 1250–1253.[CrossRef][Web of Science][Medline]
[12] Cox MM, Perlman BA, Mayor MR, et al. Acute and long-term beta-adrenergic blockade for patients with neurocardiogenic syncope. J Am Coll Cardiol 1995; 26: 1293–1298.[Abstract]
[13] Sheldon RS, Rose S, Flanagan P, Koshman ML, Killam S. Effect of beta blockers on the clinical outcome of patients after a positive isoproterenol-tilt table test. Am J Cardiol 1997; 78: 536–539.
[14] Madrid AH, Ortega J, Rebollo JG, et al. Lack of efficacy of atenolol for the prevention of neurally mediated syncope in a highly symptomatic population: A prospective, double-blind, randomized and placebo-controlled study. J Am Coll Cardiol 2001; 37: 554–559.
[15] Connolly SJ, Sheldon RS, Roberts RS, Gent M. The North American Vasovagal Pacemaker Study. A randomized trial of permanent cardiac pacing for the prevention of vasovagal syncope. J Am Coll Cardiol 1999; 33: 16–20.
[16] Sutton R, Brignole M, Menozzi C, et al. Dual chamber pacing in the treatment of neurally mediated tilt-positive cardioinhibitory syncope. Pacemaker versus no therapy: a multicentre randomized study. Circulation 2000; 102: 294–299.
[17] Waxman MB, Yao L, Cameron DA, Wald RW, Roseman J. Isoproterenol induction of vasodepressor-type reaction in vasodepressor-prone persons. Am J Cardiol 1989; 63: 58–65.[CrossRef][Web of Science][Medline]
[18] Sumiyoshi M, Nakata Y, Mineda Y, et al. Response to head-up tile testing in patients with situational syncope. Am J Cardiol 1998; 82: 1117–1118.[CrossRef][Web of Science][Medline]
[19] Natale A, Akhtar M, Jazayeri M. Provocation of hypotension during head-up tilt testing in subjects with no history of syncope or presyncope. Circulation 1995; 92: 54–58.
[20] Englund A, Frederikson M, Rosenqvist M. Head-up tilt test. A nonspecific method of evaluating patients with bifascicular block. Circulation 1997; 95: 951–954.
[21] Shen W-K, Jahangir A, Beinborn D, et al. Utility of a single-stage isoproterenol tilt table test in adults. A randomized comparison with passive head-up tilt. J Am Coll Cardiol 1999; 33: 985–990.
[22] Shvartz E and Meyerstein N. Tilt tolerance of young men and young women. Aerospace Med 1970; 41: 253–255.[Medline]
[23] Sheldon RS, Rose S, Koshman ML. Comparison of patients with syncope or unknown cause having negative or positive tilt table tests. Am J Cardiol 1997; 80: 581–585.[CrossRef][Web of Science][Medline]
[24] Calkins H, Shyr Y, Frumin H, Schork A, Morady F. The value of the clinical history in the differentiation of syncope due to ventricular tachycardia, atrioventricular block, and neurocardiogenic syncope. Am J Med 1995; 98: 365–373.[CrossRef][Web of Science][Medline]
[25] Grimm W, Degenhardt M, Hoffmann J, Menz V, Wirths A, Maisch B. Syncope recurrence can be better predicted by history than by head-up tilt testing in untreated patients with suspected neurally mediated syncope. Eur Heart J 1997; 18: 1465–1469.
[26] Natale A, Geiger MJ, Maglio C, et al. Recurrence of neurocardiogenic syncope without pharmacologic interventions. Am J Cardiol 1996; 77: 1001–1003.[CrossRef][Web of Science][Medline]
[27] Sheldon R, Rose S, Flanagan P, Koshman ML, Killam S. Risk factors for syncope recurrence after a positive tilt table test in patients with syncope. Circulation 1996; 93: 973–998.
[28] Malik P, Koshman ML, Sheldon R, Malik P. Timing of first syncope recurrence predicts syncope frequency following a positive tile table test. J Am Coll Cardiol 1997; 29: 1284–1289.[Abstract]
[29] Brignole M, Menozzi C, Gianfranchi L, Bottoni N, Lolli G. The clinical and prognostic significance of the asystolic response during the head-up tilt test. Eur J Card Pacing Electrophysiol 1992; 2: 109–113.
[30] Dhala A, Natal A, Sra J, Deshpande S, Blanck Z, Jazayeri MR, Akhtar M. Relevance of asystole during head-up tilt testing. Am J Cardiol 1995; 75: 251–254.[CrossRef][Web of Science][Medline]
[31] Sledge WH. Antecedent psychological factors in the onset of vasovagal syncope. Psychosomatic Res 1978; 40: 568–579.
[32] Linzer M, Pontinen M, Gold DT, Divine GW, Felder A, Brooks WB. Impairment of physical and psychosocial function in recurrent syncope. J Clin Epidemiol 1991; 44: 1037–1043.[CrossRef][Web of Science][Medline]
[33] Scott WA, Giacomo P, Bromberg BI, et al. Randomized comparison of atenolol and fludrocortisone acetate in the treatment of pediatric neurally mediated syncope. Am J Cardiol 1995; 76: 400–402.[CrossRef][Web of Science][Medline]
[34] Rose MS, Koshman ML, Spreng S, Sheldon RS. The relationship between health related quality of life and frequency of spells in patients with syncope. J Clin Epi 2000; 53: 1209–1216.[CrossRef][Web of Science][Medline]
[35] Linzer M, Gold DT, Pontinen M, Divine GW, Felder A, Brooks WB. Recurrent syncope as a chronic disease: Preliminary validation of a disease-specific measure of functional impairment. J Gen Intern Med 1994; 9: 181–186.[Web of Science][Medline]
[36] Mitton CR, Rose SM, Sheldon RS. Cost-utility analysis of pacemakers for the treatment of vasovagal syncope. Am J Cardiol 1999; 84: 1356–1359.[CrossRef][Web of Science][Medline]
[37] Sheldon RS, Koshman ML, Wilson W, Kieser T, Rose S. Effect of dual-chamber pacing with automatic rate-drop sensing on recurrent neurally mediated syncope. Am J Cardiol 1997; 81: 158–162.
[38] Pritchett ELC and Lee KL. Designing clinical trials for paroxysmal atrial tachycardia and other paroxysmal arrhythmias. J Clin Epidemiol 1988; 41: 851–858.[CrossRef][Web of Science][Medline]
[39] Goldman L, Gordon DJ, Rifkind BM, et al. Cost and health implications of cholesterol lowering. Circulation 1992; 85: 1960–1968.[Abstract]
[40] Morillo C, Leitch J, Yee R, Klein GJ. A placebo-controlled trial of intravenous and oral disopyramide for prevention of neurally mediated syncope induced by head-up tilt. J Am Coll Cardiol 1993; 22: 1848–1893.
[41] Brignole M, Menozzi C, Gianfranchi L, Lolli G, Bottoni N, Oddone D. A controlled trial of acute and long-term medical therapy in tilt-induced neurally mediated syncope. Am J Cardiol 1992; 70: 339–342.[CrossRef][Web of Science][Medline]
[42] Moya A, Permanyer-Miraldo G, Sagrista-Savleda J, et al. Limitations of head-up tilt test for evaluating the efficacy of therapeutic interventions in patients with vasovagal syncope: Results of a controlled study of etilefrine versus placebo. J Am Coll Cardiol 1995; 25: 65–69.[Abstract]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  Task Force members, M. Brignole, P. Vardas, E. Hoffman, H. Huikuri, A. Moya, R. Ricci, N. Sulke, W. Wieling, EHRA Scientific Documents Committee, et al. Indications for the use of diagnostic implantable and external ECG loop recorders Europace, May 1, 2009; 11(5): 671 - 687. [Full Text] [PDF]
|
|
|
|
 |
|
 S W Parry, N Steen, R S Bexton, M Tynan, and R A Kenny Pacing in elderly recurrent fallers with carotid sinus hypersensitivity: a randomised, double-blind, placebo controlled crossover trial Heart, March 1, 2009; 95(5): 405 - 409. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Brignole, R. Sutton, C. Menozzi, R. Garcia-Civera, A. Moya, W. Wieling, D. Andresen, D. G. Benditt, P. Vardas, and for the International Study on Syncope of Uncertai Early application of an implantable loop recorder allows effective specific therapy in patients with recurrent suspected neurally mediated syncope Eur. Heart J., May 1, 2006; 27(9): 1085 - 1092. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Farwell, N. Freemantle, and N. Sulke The clinical impact of implantable loop recorders in patients with syncope Eur. Heart J., February 1, 2006; 27(3): 351 - 356. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D.J. Farwell, N. Freemantle, and A.N. Sulke Use of implantable loop recorders in the diagnosis and management of syncope Eur. Heart J., July 2, 2004; 25(14): 1257 - 1263. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Croci, M. Brignole, C. Menozzi, A. Solano, P. Donateo, D. Oddone, E. Puggioni, and G. Lolli Efficacy and feasibility of isometric arm counter-pressure manoeuvres to abort impending vasovagal syncope during real life Europace, January 1, 2004; 6(4): 287 - 291. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Sheldon, S. Rose, S. Connolly, and on behalf of the POST investigators Prevention of Syncope Trial (POST): a randomized clinical trial of beta blockers in the prevention of vasovagal syncope: Rationale and study design Europace, January 1, 2003; 5(1): 71 - 75. [Abstract] [PDF]
|
|
|
|
 |
|
 C.T. P. Krediet, N. van Dijk, M. Linzer, J. J. van Lieshout, and W. Wieling Management of Vasovagal Syncope: Controlling or Aborting Faints by Leg Crossing and Muscle Tensing Circulation, September 24, 2002; 106(13): 1684 - 1689. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||